067630 — HLB Life Science Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapMomentum Trap

Annual cashflow statement for HLB Life Science Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-7,563	-55,836	-49,292	-54,360	-5,913
Depreciation
Amortisation
Non-Cash Items	3,862	49,430	31,288	33,396	-16,684
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-10,505	6,252	1,509	-13,900	5,126
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-12,388	2,010	-14,084	-29,744	-10,016
Capital Expenditures	-15,486	-20,808	-2,610	-11,654	-21,522
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	69,542	20,871	11,432	-60,990	12,639
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	54,056	62.2	8,822	-72,643	-8,883
Financing Cash Flow Items	-17,352	—	-128	800	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-21,752	-1,684	-641	102,096	4,786
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	19,907	388	-5,903	-275	-14,210